Accesswire · 30 Sept 2026positive
Tenon Medical announced the full commercial launch of its titanium 3D-printed lateral screw as part of the SImmetry+ SI Joint Fusion System, following a successful Alpha launch that generated approximately $1.2 million in incremental revenue from late Q4 2025 through Q3 2026. The company plans to expand instrument set inventory to support anticipated demand, describing the screw as the first component of a next-generation lateral SI joint fusion system.
Why it matters — This marks a commercial milestone and generates early revenue validation for Tenon's next-generation SImmetry+ system, which is expected to be followed by several additional product launches in coming quarters.
PRNewsWire · 14 Sept 2026neutral
WallachBeth Capital announced the closing of Tenon Medical's warrant inducement offering, in which an institutional investor exercised outstanding warrants to purchase an aggregate of 572,179 shares of common stock. The offering generated approximately $2,872,338 in aggregate gross proceeds.
Why it matters — TNON watchers would care because this transaction brings in new capital for the company through exercised warrants, affecting the company's share structure and financial position.
Accesswire · 14 Sept 2026neutral
Tenon Medical announced it closed a warrant inducement agreement with an institutional investor, who exercised outstanding warrants to purchase 572,179 shares of common stock for gross cash proceeds of approximately $2,872,338. In exchange for the immediate exercise, the holder received new unregistered warrants to purchase up to 858,269 shares at an exercise price of $5.02 per share.
Why it matters — The closing of this warrant exercise provides the company with additional gross proceeds while also issuing new warrants, which could result in future dilution for existing shareholders.
PRNewsWire · 11 Sept 2026positive
WallachBeth Capital announced that Tenon Medical entered into warrant exercise agreements with an institutional investor to exercise outstanding warrants for 572,179 shares of common stock, generating gross proceeds of approximately $2,872,338.
Why it matters — This warrant exercise brings fresh capital of roughly $2.9 million to Tenon Medical, providing additional funding for the company.
Accesswire · 11 Sept 2026neutral
Tenon Medical announced warrant exercise agreements with an institutional investor to immediately exercise outstanding warrants for aggregate gross proceeds of approximately $2,872,338. In consideration, the holders will receive new unregistered warrants in a private placement to purchase up to 858,269 shares of common stock at an exercise price of $5.02 per share.
Why it matters — TNON watchers would care because the company secured roughly $2.87 million in gross cash proceeds while issuing additional warrants that represent potential future dilution of common stock.
